Experience with micronized progesterone in obstetric practice
Objective. To evaluate the linked properties, efficacy, and safety profile of Prajisun in various complications of pregnancy.Khodzhaeva Z.S., Klimenchenko N.I., Muminova K.T., Gorina K.A., Frankevich V.E.
Materials and methods. This prospective cohort study enrolled 49 women with a singlet pregnancy. The viscosity of progesterones was measured using a capillary viscometer (Fungilab) at various temperature conditions.
Results. The viscosity of the most commonly used progesterones (Prajisun, Iprojin, and Utrojestan) was comparable. Thirty-six (73.4%) pregnant women used a drug vaginally; 8 (16.4%) had a combination drug (vaginally and orally); 5 (10.2%) took orally. The duration of therapy in each group was 62.0±10.2, 42.7±5.4, and 37.0±3.9 days, respectively. The oral administration of a drug was associated with impaired vaginal microbiocenosis. Eight (16.3%) patients had transient adverse events that occurred during the first week of drug use and did not require discontinuation of therapy. Pregnancy was successfully prolonged to full-term in 95.9%. There were no adverse neonatal outcomes in any case.
Conclusion. Prajisun is an effective, safe, well-tolerated, and pathogenetically justified agent for luteal phase support in IVF cycles, for treatment of pregnant women with a threatened miscarriage, and for drug prevention of premature birth.
Keywords
micronized progesterone
luteal support
threatened abortion
retrochorial hematoma
threatened premature birth
short cervix
a high risk for premature birth
drug tolerance
compliance
References
- Romero R., Dey S.K., Fisher S.J. Preterm labor: One syndrome, many causes. Science. 2014; 345(6198): 760-5. https://dx.doi.org?https://dx.doi.org/10.1126/science.1251816.
- Romero R. Prenatal medicine: The child is the father of the man. J. Matern. Fetal Neonatal Med. 2009; 22(8): 636-9. https://dx.doi.org/10.1080/14767050902784171.
- Practice Committee of the American Society for Reproductive Medicine. Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil. Steril. 2012; 98(5): 1103-11. https://dx.doi.org/10.1016/j.fertnstert.2012.06.048.
- Haas D.M., Hathaway T.J., Ramsey P.S. Progestogen for preventing miscarriage in women with recurrent miscarriage of unclear etiology. Cochrane Database Syst. Rev. 2019; (11): CD003511. https://dx.doi.org/10.1002/14651858.CD003511.pub5.
- Coomarasamy A., Harb H.M., Devall A.J., Cheed V., Roberts T.E., Goranitis I. et al. Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT. Health Technol. Assess. 2020; 24(33): 1-70. https://dx.doi.org/110.3310/hta24330.
- Мальцева Л.И., Никогосян Д.М. Эффективность микронизированного прогестерона для профилактики невынашивания беременности. Гинекология. 2015; 17(2): 56-9. [Maltseva L.I., Nikogosyan D.M. The effectiveness of micronized progesterone for the prevention of miscarriage. Gynecology. 2015; 17(2): 56-9. (in Russian)].
- Радзинский В.Е., Ордиянц И.М., Побединская О.С., Зыков Е.В. Прогестерон и репродуктивные потери. Акушерство и гинекология. 2017; 8: 109-14. https://dx.doi.org/10.18565/aig.2017.8.109-114. [Radzinsky V.E., Ordiyants I.M., Pobedinskaya O.S., Zykov E.V. Progesterone and reproductive losses. Obstetrics and Gynecology. 2017; 8: 109-14. (in Russian)]. https://dx.doi.org/10.18565/aig.2017.8.109-114.
- Гончарова С.В., Башмакова Н.В. Потеря беременности: патогенетическая терапия и ее исходы у женщин группы высокого риска. Вопросы гинекологии, акушерства и перинатологии. 2014; 13(3): 19-26. [Goncharova S.V., Bashmakova N.V. Pregnancy loss: pathogenetic therapy and its outcomes in high-risk women. Questions of gynecology, obstetrics and perinatology. 2014; 13(3): 19-26. (in Russian)].
- Bulletti C., de Ziegler D., Flamigni C., Giacomucci E., Polli V., Bolelli G., Franceschetti F. Targeted drug delivery in gynaecology: the first uterine pass effect. Hum. Reprod. 1997; 12(5): 1073-9. https://dx.doi.org/10.1093/humrep/12.5.1073.
- Joshi J.T. A review on micronization techniques. J. Pharm. Sci. Technol. 2011; 3(7): 651-81.
- ESHRE Guideline on Ovarian Stimulation for IVF/ICSI. 2017.
- Coomarasamy A., Williams H., Truchanowicz E., Seed P.T., Small R., Quenby S., Gupta P. et al. PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation, Health Technol. Assess. 2016; 20(41): 1-92. https://dx.doi.org/10.3310/hta20410.
- Coomarasamy A., Devall A.J., Brosens J.J., Quenby S., Stephenson M.D., Sierra S. et al. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence. Am. J. Obstet. Gynecol. 2020; 223(2): 167-76. https://dx.doi.org/10.1016/j.ajog.2019.12.006.
- Ogwulu C.B.O., Goranitis I., Devall A.J., Cheed V., Gallos I.D., Middleton L.J. et al. The cost-effectiveness of progesterone in preventing miscarriages in women with early pregnancy bleeding: an economic evaluation based on the PRISM trial. BJOG. 2020; 127(6): 757-67. https://dx.doi.org/10.1111/1471-0528.16068.
- McNamara H.C., Wood R., Chalmers J., Marlow N., Norrie J., MacLennan G. et al. STOPPIT Baby Follow-up Study: the effect of prophylactic progesterone in twin pregnancy on childhood outcome. PLoS One. 2015; 10(4): e0122341. https://dx.doi.org/10.1371/journal.pone.0122341.
- Devall A.J., Papadopoulou A., Podesek M., Haas D.M., Price M.J., Coomarasamy A., Gallos I.D. Progestogens for preventing miscarriage: a network meta-analysis. Cochrane Database Syst. Rev. 2021; (4): CD013792. https://dx.doi.org/10.1002/14651858.CD013792.pub2.
Received 13.07.2021
Accepted 16.07.2021
About the Authors
Zulfiya S. Khodzhaeva, MD, PhD, Professor, Deputy Director of Obstetrics Institute, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. E-mail: zkhodjaeva@mail.ru. 117997, Russia, Moscow, Ac. Oparin str., 4.Nataliya I. Klimenchenko, PhD, Senior Researcher of High Risk Pregnancy Department, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. E-mail: n_klimenchenko@oparina4.ru. 117997, Russia, Moscow, Ac. Oparin str., 4.
Kamilla T. Muminova, PhD, Researcher of High Risk Pregnancy Department, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. E-mail: k_muminova@oparina4.ru. 117997, Russia, Moscow, Ac. Oparin str., 4.
Kseniya A. Gorina, PhD, Researcher of High Risk Pregnancy Department, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. E-mail: k_gorina@oparina4.ru. 117997, Russia, Moscow, Ac. Oparin str., 4.
Vladimir E. Frankevich, PhD, Doctor of Physical and Mathematical Sciences, Head of System Biology Department, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia. E-mail: v_frankevich@oparina4.ru. 117997, Russia, Moscow, Ac. Oparin str., 4.
For citation: Khodzhaeva Z.S., Klimenchenko N.I., Muminova K.T., Gorina K.A., Frankevich V.E. Experience with micronized progesterone in obstetric practice.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2021; 7: 174-178 (in Russian).
https://dx.doi.org/10.18565/aig.2021.7.174-178
Similar Articles
